Guo-Qiang Pan

Guo-Qiang Pan

Auto-generated profile, based on publicly available information

Guo-Qiang Pan

Department of General Surgery, Qilu Hospital of Shandong University, Jinan, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2025 in Cancer Research
Verified
Journal Article
Closed access
RLRui-Zhe Li
Rui-Zhe Li
GPGuo-Qiang Pan
Guo-Qiang Pan
CXChen Xiong
Chen Xiong
ZDZi-Niu Ding
Zi-Niu Ding
TZTuan-Song Zhang
Tuan-Song Zhang
TLTao Li
Tao Li
Recently, a PARP1-dependent cell death process termed “parthanatos” that is driven by DNA damage has emerged as a crucial regulator of tissue homeostasis and tumorigenesis. Hypoxia is a hallmark of solid tumors and profoundly affects the malignant phenotypes of cancer cells. In this study, we investigated the cross-talk between parthanatos and hypoxia. Despite causing DNA damage, hypoxia failed to induce parthanatos in hepatocellular carcinoma (HCC). The creatine transporter SLC6A8 promoted parthanatos antagonism and malignant phenotypes in hypoxic HCC cells. Hypoxia-induced creatine accumulation drove metabolic reprogramming and antagonized parthanatos. Mechanistically, creatine elevated serpin peptidase inhibitor class E member 1 (SERPINE1) expression through MPS1-mediated Smad2/3 phosphorylation and formed a creatine/SERPINE1/hypoxia-inducible factor 1α–positive feedback loop. SERPINE1 facilitated ubiquitin-specific protease 10 (USP10)–mediated deubiquitination and stabilization of pyruvate kinase, liver, and red blood cell by forming a SERPINE1–USP10–pyruvate kinase, liver, and red blood cell complex. USP10 contained a strong poly(ADP-ribose)–binding motif, and SERPINE1 reversed the attenuated deubiquitination activity of USP10 caused by the direct binding of poly(ADP-ribose) under hypoxia. The SLC6A8 inhibitor RGX-202 exerted potent antitumor activity alone and in combination with lenvatinib in patient-derived xenografts and primary HCC mouse models. Overall, this study identified intracellular creatine accumulation as a mechanism that allows hypoxic cancer cells to circumvent parthanatos and as a therapeutic target in HCC. Significance: The creatine transporter SLC6A8 drives creatine uptake in hypoxic cancer cells to induce parthanatos antagonism and metabolic reprogramming, which can be overcome by inhibiting SLC6A8 as a strategy for treating hepatocellular carcinoma.

1 October 2025
Verified
Other
Open access
RLRui-Zhe Li
Rui-Zhe Li
GPGuo-Qiang Pan
Guo-Qiang Pan
CXChen Xiong
Chen Xiong
ZDZi-Niu Ding
Zi-Niu Ding
TZTuan-Song Zhang
Tuan-Song Zhang
TLTao Li
Tao Li
Recently, a PARP1-dependent cell death process termed “parthanatos” that is driven by DNA damage has emerged as a crucial regulator of tissue homeostasis and tumorigenesis. Hypoxia is a hallmark of solid tumors and profoundly affects the malignant phenotypes of cancer cells. In this study, we investigated the cross-talk between parthanatos and hypoxia. Despite causing DNA damage, hypoxia failed to induce parthanatos in hepatocellular carcinoma (HCC). The creatine transporter SLC6A8 promoted parthanatos antagonism and malignant phenotypes in hypoxic HCC cells. Hypoxia-induced creatine accumulation drove metabolic reprogramming and antagonized parthanatos. Mechanistically, creatine elevated serpin peptidase inhibitor class E member 1 (SERPINE1) expression through MPS1-mediated Smad2/3 phosphorylation and formed a creatine/SERPINE1/hypoxia-inducible factor 1α–positive feedback loop. SERPINE1 facilitated ubiquitin-specific protease 10 (USP10)–mediated deubiquitination and stabilization of pyruvate kinase, liver, and red blood cell by forming a SERPINE1–USP10–pyruvate kinase, liver, and red blood cell complex. USP10 contained a strong poly(ADP-ribose)–binding motif, and SERPINE1 reversed the attenuated deubiquitination activity of USP10 caused by the direct binding of poly(ADP-ribose) under hypoxia. The SLC6A8 inhibitor RGX-202 exerted potent antitumor activity alone and in combination with lenvatinib in patient-derived xenografts and primary HCC mouse models. Overall, this study identified intracellular creatine accumulation as a mechanism that allows hypoxic cancer cells to circumvent parthanatos and as a therapeutic target in HCC.Significance:The creatine transporter SLC6A8 drives creatine uptake in hypoxic cancer cells to induce parthanatos antagonism and metabolic reprogramming, which can be overcome by inhibiting SLC6A8 as a strategy for treating hepatocellular carcinoma.

1 October 2025
Verified
Other
Open access
RLRui-Zhe Li
Rui-Zhe Li
GPGuo-Qiang Pan
Guo-Qiang Pan
CXChen Xiong
Chen Xiong
ZDZi-Niu Ding
Zi-Niu Ding
TZTuan-Song Zhang
Tuan-Song Zhang
TLTao Li
Tao Li
Supplementary Figure 8. Combining RGX-202 with lenvatinib exhibits potent antitumor effects in PDX models. (A, B) Colony formation assay was used to determine the colony formation ability of hypoxic HCC cells across different treatment groups. (C-F) Cell invasion and migration of hypoxic HCC cells across different treatment groups were evaluated by transwell assay. Scale bars, 50 μm. (G) The ECAR and OCR were measured in hypoxic HCC cells across different treatment groups. (H, I) CCK-8 (H) and EdU incorporation assays (I) were performed to evaluate the effect of SERPINE1 overexpression on cell proliferation under RGX-202 treatment. Scale bars, 50 μm. (J) Colony formation assay was used to determine the effect of SERPINE1 overexpression on colony formation ability under RGX-202 treatment. (K, L) Transwell assays were used to evaluate the effect of SERPINE1 overexpression on cell invasion and migration under RGX-202 treatment. Scale bars, 50 μm. (M, N) The ECAR and OCR were measured in hypoxic HCC cells under RGX-202 treatment with or without SERPINE1-overexpression. (O) Analysis of tumor numbers in the livers of the indicated mice (n = 5). (P) Determination of circulating ALT and AST levels in the indicated mice. (Q) Gross images of PDX model derived from low SLC6A8 expression specimens (n = 6). For cell experiments, n = 3 independent experiments. Means ± SD are shown; *P < 0.05, **P < 0.01, ***P < 0.001, and ns indicates no significant difference.

1 October 2025
Verified
Other
Open access
RLRui-Zhe Li
Rui-Zhe Li
GPGuo-Qiang Pan
Guo-Qiang Pan
CXChen Xiong
Chen Xiong
ZDZi-Niu Ding
Zi-Niu Ding
TZTuan-Song Zhang
Tuan-Song Zhang
TLTao Li
Tao Li
Supplementary Figure 3. Creatine antagonizes parthanatos by enhancing the metabolic reprogramming of hypoxic HCC cells. (A) Heatmap of the DEGs in hypoxic Huh7 SLC6A8-knockdown cells compared with control cells. (B-C) KEGG and GO analyses of Huh7 RNA-seq data. (D) Gene set enrichment analysis of Huh7 cells. The normalized enrichment score (NES) was shown. (E, F) 2-NBDG absorbance (E) and glucose uptake (F) of hypoxic HCC cells were measured upon creatine supplementation. (G) HK and PK activity of hypoxic HCC cells were measured. (H, I) The ECAR (H) and OCR (I) were measured upon creatine supplementation in hypoxic HCC cells using a XF Extracellular Flux Analyzer. (J) ROS of hypoxic HCC cells was measured using flow cytometry. (K, L) The MDA level (K) and GSH/GSSG ration (L) of hypoxic HCC cells were measured. (M, N) The ECAR of HCC cells with or without MNNG under normoxia or hypoxia were measured. (O) Western blot examined the PAR polymer accumulation in hypoxic HCC cells with or without 2-DG (10mM) administration. (P) Western blot showed the phosphorylation levels of Smad2 and Smad3 in hypoxic HCC cells upon creatine supplementation. (Q, R) Western blot analysis was performed to evaluate the effects of SB525334 (Q) and AZ3146 (R) on Smad2/3 phosphorylation. (S) Western blot showed the knockdown efficiency of MPS1. (T) Western blot showed the Smad2/3 phosphorylation of hypoxic HCC cells with MPS1-knockdown rescued by wild-type or mutant MPS1 in the presence or absence of creatine treatment. (U) IF and western blot analyses examined the nuclear translocation of Smad4 in hypoxic HCC cells. n = 3 independent experiments. Means ± SD are shown; *P < 0.05, **P < 0.01, ***P < 0.001, and ns indicates no significant difference.


1 October 2025
Verified
Other
Open access
RLRui-Zhe Li
Rui-Zhe Li
GPGuo-Qiang Pan
Guo-Qiang Pan
CXChen Xiong
Chen Xiong
ZDZi-Niu Ding
Zi-Niu Ding
TZTuan-Song Zhang
Tuan-Song Zhang
TLTao Li
Tao Li
Supplementary Figure 6. The USP10-PKLR axis serves as the key effector of creatine/SERPINE1-mediated Warburg effect and parthanatos antagonism. (A, B) Confocal microscopy (A) and cell fractionation (B) assays determining the subcellular localization of SERPINE1 in HCC cells. Scale bars, 10 μm. (C) Confocal microscopy analysis showing the colocalization of SERPINE1 and PKLR in HCC cells. Scale bars, 10 μm. (D) Endogenous co-IP assays confirmed the interaction between SERPINE1 and PKLR in HCC cells. (E, F) qRT-PCR was used to analyze the mRNA level of PKLR in SERPINE1-knockdown (E) and overexpression (F) cells. (G) Relative PKLR protein levels after CHX treatment. (H) Western blot analysis of the ubiquitination of PKLR upon SERPINE1 knockdown in HCC cells. (I, J) Endogenous co-IP assays confirmed the presence of the SERPINE1-PKLR-USP10 complex based on the LC-MS/MS data. (K) Confocal microscopy analysis showing the colocalization of PKLR and USP10 in HCC cells. Scale bars, 10 μm. (L, M) Endogenous and exogenous co-IP assays confirmed the interaction of PKLR and USP10 in HCC cells. (N, O) Western blotting analysis assessed the PARyaltion of USP10 in HCC cells upon MNNG or Olaparib administration. (P) Western blot analysis showing the degradation rate of USP10 in control and MNNG-treated groups. n = 3 independent experiments. Means ± SD are shown; *P < 0.05, **P < 0.01, ***P < 0.001, and ns indicates no significant difference.